| Primary |
| Eczema |
20.0% |
| Hypersensitivity |
20.0% |
| Product Used For Unknown Indication |
20.0% |
| Sedation |
20.0% |
| Urticaria |
20.0% |
|
| Anaphylactic Reaction |
20.0% |
| Erythema |
20.0% |
| Tardive Dyskinesia |
20.0% |
| Toxic Epidermal Necrolysis |
20.0% |
| Vomiting |
20.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
13.1% |
| Thrombosis Prophylaxis |
6.5% |
| Pruritus |
6.1% |
| Chronic Obstructive Pulmonary Disease |
5.6% |
| Dermatitis |
5.6% |
| Grand Mal Convulsion |
5.6% |
| Rash |
5.6% |
| Supraventricular Tachycardia |
5.6% |
| Tachycardia Paroxysmal |
5.6% |
| Prophylaxis |
5.1% |
| Premedication |
4.7% |
| Product Used For Unknown Indication |
4.7% |
| Sleep Disorder |
4.7% |
| Epilepsy |
3.7% |
| Breast Cancer Metastatic |
3.3% |
| Pain |
3.3% |
| B-cell Small Lymphocytic Lymphoma |
2.8% |
| Chronic Lymphocytic Leukaemia |
2.8% |
| Endocarditis |
2.8% |
| Infection |
2.8% |
|
| Toxic Epidermal Necrolysis |
36.1% |
| Vomiting |
16.7% |
| Pharmaceutical Product Complaint |
13.9% |
| Circulatory Collapse |
8.3% |
| Hypoalbuminaemia |
5.6% |
| Weight Decreased |
5.6% |
| Erythema |
2.8% |
| Gastric Perforation |
2.8% |
| Post Procedural Complication |
2.8% |
| Rash |
2.8% |
| Stevens-johnson Syndrome |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
16.8% |
| Drug Use For Unknown Indication |
14.7% |
| Premedication |
13.8% |
| Chronic Lymphocytic Leukaemia |
6.5% |
| Breast Cancer |
6.4% |
| Prophylaxis |
5.6% |
| Diarrhoea |
4.0% |
| Hypertension |
3.7% |
| Non-small Cell Lung Cancer |
2.9% |
| Ovarian Cancer |
2.8% |
| Pain |
2.8% |
| Diffuse Large B-cell Lymphoma |
2.6% |
| B-cell Small Lymphocytic Lymphoma |
2.5% |
| Colorectal Cancer Metastatic |
2.4% |
| Rheumatoid Arthritis |
2.3% |
| Anaemia |
2.1% |
| Breast Cancer Metastatic |
2.1% |
| Metastases To Bone |
2.1% |
| Erosive Duodenitis |
1.9% |
| Sinusitis |
1.9% |
|
| Pneumonia |
7.9% |
| Rash |
6.9% |
| Throat Tightness |
6.9% |
| Toxic Epidermal Necrolysis |
6.9% |
| Visual Impairment |
6.9% |
| Pulmonary Embolism |
5.9% |
| Respiratory Failure |
5.9% |
| Sinusitis |
5.9% |
| Product Quality Issue |
5.0% |
| Urticaria |
5.0% |
| Vomiting |
5.0% |
| General Physical Health Deterioration |
4.0% |
| Infusion Related Reaction |
4.0% |
| Malignant Neoplasm Progression |
4.0% |
| Petechiae |
4.0% |
| Pyrexia |
4.0% |
| Disseminated Tuberculosis |
3.0% |
| Febrile Neutropenia |
3.0% |
| Hypotension |
3.0% |
| Large Granular Lymphocytosis |
3.0% |
|
| Interacting |
| Premedication |
60.0% |
| B-cell Lymphoma |
20.0% |
| Breast Cancer |
20.0% |
|
|
